Subtype
Hypermobility spectrum disorder (HSD)
The residual category for symptomatic hypermobility falling short of hEDS criteria. Whether HSD and hEDS are meaningfully distinct is an open research question.
| Classification | Related hypermobility spectrum |
|---|---|
| Inheritance | unknown |
| Genes | None confirmed |
| Genetic status | no known gene |
| Prevalence | Unresolved. A 2019 Wales study found about 1 in 500 people with a recorded diagnosis of EDS or joint hypermobility syndrome, an older term covering both hEDS and HSD |
| Distinguishing features | Symptomatic joint hypermobility not meeting the strict 2017 hEDS criteria; a clinical diagnosis |
| Last checked | 2026-09-16 |
Records about HSD
Subluxation, braces, taping, and joint-stabilization self-management
patient-reported patternevidence: community signalMuch of the practical discussion in patient communities is about joints that partly slip out of place (subluxation) rather than fully dislocate. Members swap taping, bracing, and stabilizing techniques, often for subluxations no doctor has confirmed. Clinical literature treats subluxation as close to, but not itself, a diagnostic criterion; the community discussion is about day-to-day management rather than diagnosis.
Members treat finding a physical therapist as a search problem. They share directories and word-of-mouth referrals and look for therapists who avoid the generic exercise programs members consider harmful.
Diagnosis navigation and specialist-finding strategies
patient-reported patternevidence: community signalindependent evidence agreesMembers share advice on which specialists diagnose EDS, which tests matter, and how to prepare for an appointment, in response to diagnostic delays that often last years. This is peer advice, not a clinical pathway.
The “trifecta”: hEDS, POTS, and mast cell activation reported together
patient-reported patternevidence: community signalindependent evidence agreesPatient communities often describe hEDS, POTS (a form of dysautonomia), and mast cell activation syndrome (MCAS) occurring together, and call the combination the “trifecta”. In a Global Registry survey of 505 people with hEDS, POTS and MCAS were among the diagnoses participants most often endorsed as accurate. Whether the three share a mechanism is unknown.
The 2017 series and subsequent cohort work document gastrointestinal dysmotility (reflux, gastroparesis, constipation) and autonomic dysfunction (orthostatic intolerance, POTS) as leading comorbidity domains in hEDS/HSD. In a 2025 survey at a German EDS clinic, musculoskeletal pain and joint instability were the most common first symptoms.
The 2017 hEDS criteria require hypermobility, systemic manifestations, and exclusion
findingevidence: establishedone underlying sourcehEDS diagnosis under the 2017 International Classification requires (1) generalized joint hypermobility by Beighton score, (2) two or more of systemic manifestations, positive family history, or musculoskeletal complications, and (3) exclusion of other connective-tissue disorders. Unlike every other subtype, hEDS has no molecular confirmation test.
The 2017 framework (Castori et al.) separated symptomatic joint hypermobility into hEDS when the strict criteria are met and HSD when they are not. The boundary is contested. The criteria were designed to define a more uniform group for research, not to declare HSD benign, and the hEDS/HSD criteria review study is ongoing.
HEDGE is studying the genetics of 1,000 people with hEDS
research programevidence: emergingone underlying sourceHEDGE (Hypermobile Ehlers-Danlos Genetic Evaluation), listed among The Ehlers-Danlos Society's research programs, is studying the genetics of 1,000 people with hEDS. In October 2025 the society said it expected the first publications in late 2025 or early 2026, and that timelines may shift.
Clinical guidance gives individualized physical therapy (strengthening, proprioceptive work, and pacing) a central role in managing hEDS and HSD. A 2017 paper on physical therapy by Engelbert and colleagues says the research on managing these conditions is limited in size and quality, so the advice rests more on expert consensus and clinical experience than on large trials.
Studies of the diagnostic journey in hEDS describe medical gaslighting and post-traumatic stress, and management guidance includes psychological support. A 2025 qualitative study of people with hEDS says physicians should be aware of possible medical post-traumatic stress disorder and highlights the importance of trauma-informed care.
A 2025 qualitative study describes the hEDS diagnostic journey as traumatic
findingevidence: probableindependent evidence agreesA qualitative study of people diagnosed with hEDS, published in BMJ Connections Clinical Genetics and Genomics in December 2025, found that experiences with providers ranged from harmful dismissal to validation, and that a diagnosis brought both validation and grief. The authors say physicians who diagnose and treat hEDS should be aware of possible medical post-traumatic stress disorder and past experiences of medical gaslighting. In a separate Global Registry survey of people with hEDS, anxiety and depression were among the most common other diagnoses they had received.
Pain and joint instability lead the symptoms reported at a German EDS clinic
findingevidence: probableA survey of 99 adults diagnosed at the EDS clinic of University Hospital Cologne, 80 of them with hEDS or HSD, was published in 2025. Musculoskeletal pain and joint instability, including repeated subluxations and dislocations, were the most common first symptoms. Pain was the problem respondents most often said severely affected daily activities (60.2%), followed by joint instability (38.8%), other orthopedic problems (36.7%), digestive complaints (35.7%), and fatigue (32.7%). The results come from one specialist clinic.
In a 2025 survey at a German EDS clinic, 32.7% of respondents said fatigue severely affected their daily activities, after pain, joint instability, other orthopedic problems, and digestive complaints. Fatigue is not one of the 2017 hEDS diagnostic criteria.
Records that apply to every EDS type
- Medication, dental, and procedural caution knowledge
- The 2017 classification papers cover symptoms beyond joints and skin
- Twelve subtypes require molecular confirmation; hEDS remains clinical
- Criteria-era drift makes old and new EDS literature non-equivalent
- The 2017 classification groups EDS genes by the process they affect
- Beighton score published for epidemiological joint-mobility assessment
- Berlin nosology expands EDS to eleven numbered types
- Villefranche nosology consolidates to six types
- 2017 International Classification defines thirteen subtypes
- Local anesthetic resistance in EDS: patient reports, two surveys, and a 2026 trial
- A 2017 review of pain management in EDS
- Surgical and tissue-handling caution
- Diagnosing EDS and HSD often takes years
- The DICE Global Registry collects patient-reported data on EDS and HSD
- EDS ECHO teaches clinicians and community members about EDS
- The ClinicalTrials.gov EDS portfolio
- Orphanet and GARD keep reference records for rare diseases, including EDS
Sources
- A framework for the classification of joint hypermobility and related conditions
- The 2017 international classification of the Ehlers-Danlos syndromes
- Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison